Decheng Capital Management III (Cayman)’s Aura Biosciences AURA Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$18.2M	Buy	1,163,123 +869,790	+297%	+$9.36M	6.09%	3
2023 Q2	$3.62M	Hold	293,333	–	–	1.14%	15
2023 Q1	$2.72M	Hold	293,333	–	–	1.1%	18
2022 Q4	$3.08M	Buy	293,333 +83,333	+40%	+$1.06M	1.15%	17
2022 Q3	$3.81M	Hold	210,000	–	–	1.38%	18
2022 Q2	$2.98M	Hold	210,000	–	–	1.13%	17
2022 Q1	$4.62M	Buy	+210,000	New	+$4M	1.42%	14

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s AURA Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) increased its Aura Biosciences (AURA) stake by 297% in Q3 2023, buying an estimated $9.36M and bringing the position to 1,163,123 shares worth $18.2M. The position accounts for 6.09% of the portfolio, ranked #3.

Decheng Capital Management III (Cayman) first reported a position in AURA in Q1 2022 and has held it in 7 quarters since. 64 funds tracked by Wall St. Rank hold AURA as of Q3 2023.

Decheng Capital Management III (Cayman) held 1,163,123 shares of Aura Biosciences worth $18.2M as of Q3 2023.
Decheng Capital Management III (Cayman) bought 869,790 Aura Biosciences shares in Q3 2023, an estimated $9.36M.
Aura Biosciences made up 6.09% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #3 holding.
Decheng Capital Management III (Cayman) first reported a position in Aura Biosciences in Q1 2022 and has held it in 7 quarters since.
64 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.